Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL484745 | 0.94 | ALDH1A1 (0.50) | ALDH1A1HSD17B10NAMPTCYP1A2CYP2C9 | |
| SCHEMBL30248648 | 0.94 | CYP3A4 (0.41) | ALDH1A1HSD17B10NAMPTHPGDCYP1A2 | |
| SCHEMBL484405 | 0.94 | CYP3A4 (0.41) | ALDH1A1HSD17B10NAMPTHPGDCYP1A2 | |
| SCHEMBL18686085 | 0.94 | CYP3A4 (0.41) | ALDH1A1HSD17B10NAMPTHPGDCYP1A2 | |
| Hydrochloric Acid SCHEMBL5322449 | 0.93 | ALDH1A1 (0.49) | ALDH1A1HSD17B10NAMPTCYP1A2CYP2C9 | |
| Oxalic Acid SCHEMBL29782913 | 0.91 | HSD17B10 (0.49) | ALDH1A1HSD17B10NAMPTCYP1A2CYP2C9 | |
| SCHEMBL2177880 | 0.90 | HPGD (0.42) | ALDH1A1HSD17B10HPGDCYP1A2CYP2C9 | |
| SCHEMBL14801521 | 0.90 | ALDH1A1 (0.42) | ALDH1A1HSD17B10NAMPTHPGDCYP3A4 | |
| Hydrochloric Acid SCHEMBL20512854 | 0.89 | HPGD (0.41) | ALDH1A1HPGDCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL18047957 | 0.87 | USP2 (0.41) | ALDH1A1HPGDUSP2SMN1; SMN2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| EP-4536650-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025039676-A1 | PAN-KRAS PROTEIN TARGETED DEGRADER COMPOUND AND USE THEREOF | 贝达药业股份有限公司 | 2025-02-27 | — | — | WO | disclosed |
| CN-119317623-A | Tricyclic quinolone BCL6 bifunctional degradation agents | 树线生物科学公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-3743425-B1 | 2,8-DIACYL-2,8-DIAZASPIRO[5.5]UNDECANE COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240287091-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2024-08-29 | — | — | US | disclosed |
| WO-2023240038-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-111793077-B | PD-1/PD-L1 small molecule inhibitor and application thereof in medicines | 东莞市东阳光新药研发有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-11414418-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-16 | — | — | US | disclosed |
| US-20220112187-A1 | PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-04-14 | — | — | US | disclosed |
| US-9493474-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20140288042-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2014-09-25 | — | — | US | disclosed |
| EP-2773351-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| WO-2013066718-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-2411381-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2010108651-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2010-09-30 | — | — | WO | disclosed |
| WO-2009102537-A1 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112187-A1 | PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, KCNJ1, KCNJ11 | ALDH1A1 1043/4885HSD17B10 4394/4885NAMPT 2049/4885 |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | ALDH1A1 2086/4885HSD17B10 4072/4885NAMPT 2232/4885 |
| US-20240287091-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | ALDH1A1 512/4885HSD17B10 278/4885NAMPT 3709/4885 |
| US-11414418-B2 | Compounds useful as immunomodulators | CD74, HLA-DRB1, CD47 | ALDH1A1 1130/4885HSD17B10 3503/4885NAMPT 656/4885 |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | ALDH1A1 512/4885HSD17B10 278/4885NAMPT 3709/4885 |
| US-20140288042-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ2, KCNJ11, KCNK2 | ALDH1A1 1827/4885HSD17B10 3557/4885NAMPT 2670/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | ALDH1A1 2086/4885HSD17B10 4072/4885NAMPT 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.